A Theoretical Interpretation of Litigation Concerning Special Representative of Securities and A Reflection on Relevant Rules —On the Class Action Case of Kangmei Pharmaceuticals

SU Hesheng,YANG Yanyan

DOI: https://doi.org/10.13796/j.cnki.1001-5019.2023.02.013

2023-01-01

Abstract:As the first securities class action case in China, the Kangmei Pharmaceuticals case has opened up a new path for the resolution of securities group disputes. However, due to the lack of a systematic legislative framework and refined practical guidelines, the case reveals a number of issues worth pondering. In terms of the plaintiff’s eligibility, core features of “insurance-agency-led procedures” and “express exit model” distinguish the special representative’s litigation from other group litigation. The special representative lawsuit is essentially a group lawsuit, and the right to enforce the lawsuit by the insurance agency is derived from the statutory arbitrary action. In terms of the judicial determination of the defendant’s liability, the expansion of the sole director’s liability in the case is worthy of consideration in the substantive dimension and the judicial goal of one-time resolution of securities group disputes and prevention of contradictory adjudication needs to be rationally balanced in the procedural dimension. As the “sole plaintiff”, the appropriateness and fairness of the selection and screening of the case by the investment insurance agency must be addressed. In addition, in order to steadily promote the progressive development of securities class action lawsuits, it is necessary to structurally optimize the special representative litigation system based on procedural jurisprudence, by clarifying the relationship between the innovative and traditional functions of insurance agencies, delineating the stages of investor withdrawal from litigation and reflecting on the payment and sharing of litigation costs.